Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus chemotherapy vs chemotherapy plus placebo after first-line osimertinib progression in EGFR-mutated NSCLC
CTR20220910Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in EGFR-mutated non-small cell lung cancer, sponsored by AstraZeneca. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on CTR20220910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220910.